Demand for weight management medications is at an all-time high. Any medication that can produce clinically meaningful weight loss is great news for patients, but hospital and health system leaders worry that Wegovy and similar drugs will erode their bariatric surgery volumes and revenue. While this concern is valid, it’s a singular service line perspective. Instead, we want to challenge healthcare leaders to think like an integrated system and consider leveraging comprehensive obesity care to drive surgical services growth by: 

1. Improving surgical outcomes
2. Increasing surgical volumes
3. Reducing surgical costs

When health systems and providers integrate different obesity care pathways under one umbrella, they can drive growth for surgical services by improving outcomes, increasing volume, and decreasing costs.